Cite
HARVARD Citation
Ronot, M. et al. (2014). Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib. Oncologist. pp. 394-402. [Online].